Trump Secures Final Drug Pricing Deal with Regeneron: $27B Investment, Medicaid Price Cuts, and FDA-Approved Gene Therapy Otarmeni at No Cost to Patients
On Thursday, President Trump announced the completion of 17 drug pricing agreements initiated by his administration, with Regeneron Pharmaceuticals agreeing to lower Medicaid prices for several therapies, offer its cholesterol-lowering ... Read More